The FDA announced that it has completed its evaluation of a report of a patient who died after the first dose of the multiple sclerosis drug Gilenya (fingolimod). The agency has also evaluated additional clinical trials and postmarket data for Gilenya, including reports of patients who died of cardiovascular events and unknown causes.

After a prolonged period of shortage, Cal-Heparine ampoules provided by Amoun Pharmaceuticals, are now again available.

Omega-3’s, -6’s and -9’s are all fatty acids which play a crucial role in the human body and contribute to its well-being and proper functioning. The difference between one fatty acid and another boils down to tiny molecules; slight differences in the molecular configuration allow each of these fatty acids to work in its own way to benefit the body.